FDA OKs Varisolve varicose vein therapy trial:
This article was originally published in Clinica
BTG's subsidiary Provensis has gained approval from the US FDA to begin a pilot clinical study of its noninvasive procedure for treating varicose veins. The technique, called Varisolve, involves injecting a microfoam version of a standard sclerosing liquid into the vein under ultrasound guidance. Efficacy data from an ongoing trial in Europe are expected to become available by the end of the year, at which time BTG plans to begin discussions with potential sales and marketing partners. London, UK-based BTG forecasts 2006 and 2005 launch dates for Varisolve in the US and in Europe, respectively.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.